Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

Chimeric Antigen Receptor (CAR) T cell therapies – adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to three recent US Food and Drug Administration approvals....

Descripción completa

Detalles Bibliográficos
Autores principales: Boyiadzis, Michael M., Dhodapkar, Madhav V., Brentjens, Renier J., Kochenderfer, James N., Neelapu, Sattva S., Maus, Marcela V., Porter, David L., Maloney, David G., Grupp, Stephan A., Mackall, Crystal L., June, Carl H., Bishop, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278156/
https://www.ncbi.nlm.nih.gov/pubmed/30514386
http://dx.doi.org/10.1186/s40425-018-0460-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278156/
https://www.ncbi.nlm.nih.gov/pubmed/30514386
http://dx.doi.org/10.1186/s40425-018-0460-5

Ejemplares similares